Discussion of germline genetic modification continues, most recently in the House of Representatives Research and Technology Subcommittee, Committee on Science, Space, and Technology. The Subcommittee’s June 16 hearing gives this post its title. Video is available, as are pdfs of the four witness statements.
Victor J. Dzau, President of the Institute of Medicine (soon to be the National Academy of Medicine) outlined the plans for the Academies Initiative. There will be two parts to this:
- a global summit to examine recent scientific developments in human gene editing and the range of associated ethical and governance issues
- a concurrent expert committee to conduct a comprehensive study on human gene-editing research
The exact date of the global summit, which will be held in “late fall,” has not yet been announced, and the study, which may take a year, does not yet have a final “statement of task.” The day before the hearing the advisory group for the initiative was announced. The 14 members include six of the 18 signatories of the March paper in Science that called for a moratorium (including David Baltimore, Paul Berg and Jennifer Doudna; notable omissions include George Church and Hank Greely) but none of the 5 authors of the stronger Nature paper. All but two members are American, the exceptions being Robin Lovell-Badge (UK) and Xu Zhihong (China).
The other witnesses at the Subcommittee hearing were Doudna, who gave a brief overview [pdf] of gene editing and its possible applications; Elizabeth McNally, who notably included [pdf] the perspective of families who might want to apply such technologies; and Jeffrey Kahn, whose presentation [pdf] included a useful overview of US regulatory mechanisms but seemed to overlook previous international agreements that might serve as models.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.